MaaT Pharma Statistics

Total Valuation

MaaT Pharma has a market cap or net worth of EUR 110.61 million. The enterprise value is 103.19 million.

Market Cap	110.61M
Enterprise Value	103.19M

Important Dates

The last earnings date was Monday, March 30, 2026.

Earnings Date	Mar 30, 2026
Ex-Dividend Date	n/a

Share Statistics

MaaT Pharma has 18.84 million shares outstanding. The number of shares has increased by 21.97% in one year.

Current Share Class	18.84M
Shares Outstanding	18.84M
Shares Change (YoY)	+21.97%
Shares Change (QoQ)	+10.88%
Owned by Insiders (%)	1.42%
Owned by Institutions (%)	13.32%
Float	9.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.45
PB Ratio	61.49
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.32
EV / Sales	22.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.32

Financial Position

The company has a current ratio of 1.94, with a Debt / Equity ratio of 9.69.

Current Ratio	1.94
Quick Ratio	1.87
Debt / Equity	9.69
Debt / EBITDA	n/a
Debt / FCF	-1.07
Interest Coverage	-23.58

Financial Efficiency

Return on equity (ROE) is -511.92% and return on invested capital (ROIC) is -81.62%.

Return on Equity (ROE)	-511.92%
Return on Assets (ROA)	-44.74%
Return on Invested Capital (ROIC)	-81.62%
Return on Capital Employed (ROCE)	-107.82%
Weighted Average Cost of Capital (WACC)	6.50%
Revenue Per Employee	80,786
Profits Per Employee	-554,661
Employee Count	59
Asset Turnover	0.11
Inventory Turnover	23.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.84% in the last 52 weeks. The beta is 0.43, so MaaT Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	-0.84%
50-Day Moving Average	6.50
200-Day Moving Average	5.23
Relative Strength Index (RSI)	49.59
Average Volume (20 Days)	65,192

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MaaT Pharma had revenue of EUR 4.52 million and -31.06 million in losses. Loss per share was -1.95.

Revenue	4.52M
Gross Profit	2.80M
Operating Income	-29.73M
Pretax Income	-31.06M
Net Income	-31.06M
EBITDA	-29.41M
EBIT	-29.73M
Loss Per Share	-1.95

Full Income Statement

Balance Sheet

The company has 24.87 million in cash and 17.44 million in debt, giving a net cash position of 7.43 million or 0.39 per share.

Cash & Cash Equivalents	24.87M
Total Debt	17.44M
Net Cash	7.43M
Net Cash Per Share	0.39
Equity (Book Value)	1.80M
Book Value Per Share	0.10
Working Capital	16.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.72 million and capital expenditures -608,000, giving a free cash flow of -16.33 million.

Operating Cash Flow	-15.72M
Capital Expenditures	-608,000
Depreciation & Amortization	318,000
Net Borrowing	353,000
Free Cash Flow	-16.33M
FCF Per Share	-0.87

Full Cash Flow Statement

Margins

Gross Margin	61.80%
Operating Margin	-657.14%
Pretax Margin	-686.58%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MaaT Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.97%
Shareholder Yield	-21.97%
Earnings Yield	-28.08%
FCF Yield	-14.76%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

MaaT Pharma has an Altman Z-Score of -1.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.41
Piotroski F-Score	3